Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

G Schernthaner; Anthony Barnett; DJ Betteridge; R Carmena; A Ceriello; B Charbonnel; M Hanefeld; R Lehmann; MT Malecki; R Nesto; V Pirags; A Scheen; J Seufert; A Sjoholm; A Tsatsoulis; R DeFronzo

doi:10.1007/s00125-010-1702-3

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

G Schernthaner, Anthony Barnett, DJ Betteridge, R Carmena, A Ceriello, B Charbonnel, M Hanefeld, R Lehmann, MT Malecki, R Nesto, V Pirags, A Scheen, J Seufert, A Sjoholm, A Tsatsoulis, R DeFronzo

Birmingham Medical School

Research output: Contribution to journal › Article

97 Citations (Scopus)

Abstract

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.

Original language	English
Pages (from-to)	1258-1269
Number of pages	12
Journal	Diabetologia
Volume	53
Issue number	7
DOIs	https://doi.org/10.1007/s00125-010-1702-3
Publication status	Published - 1 Jul 2010

Keywords

Glucose-lowering therapy
Hyperglycaemia
EASD consensus statement
ADA Consensus Statement
Cardiovascular risk
Type 2 diabetes
Algorithm

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00125-010-1702-3

Cite this

Schernthaner, G., Barnett, A., Betteridge, DJ., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, MT., Nesto, R., Pirags, V., Scheen, A., Seufert, J., Sjoholm, A., Tsatsoulis, A., & DeFronzo, R. (2010). Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia, 53(7), 1258-1269. https://doi.org/10.1007/s00125-010-1702-3

@article{92b82d1b3f2c4bf492a6adcf715e147e,

title = "Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis",

abstract = "The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.",

keywords = "Glucose-lowering therapy, Hyperglycaemia, EASD consensus statement, ADA Consensus Statement, Cardiovascular risk, Type 2 diabetes, Algorithm",

author = "G Schernthaner and Anthony Barnett and DJ Betteridge and R Carmena and A Ceriello and B Charbonnel and M Hanefeld and R Lehmann and MT Malecki and R Nesto and V Pirags and A Scheen and J Seufert and A Sjoholm and A Tsatsoulis and R DeFronzo",

year = "2010",

month = jul,

day = "1",

doi = "10.1007/s00125-010-1702-3",

language = "English",

volume = "53",

pages = "1258--1269",

journal = "Diabetologia",

issn = "1432-0428",

publisher = "Springer",

number = "7",

}

Schernthaner, G, Barnett, A, Betteridge, DJ, Carmena, R, Ceriello, A, Charbonnel, B, Hanefeld, M, Lehmann, R, Malecki, MT, Nesto, R, Pirags, V, Scheen, A, Seufert, J, Sjoholm, A, Tsatsoulis, A & DeFronzo, R 2010, 'Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis', Diabetologia, vol. 53, no. 7, pp. 1258-1269. https://doi.org/10.1007/s00125-010-1702-3

TY - JOUR

T1 - Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

AU - Schernthaner, G

AU - Barnett, Anthony

AU - Betteridge, DJ

AU - Carmena, R

AU - Ceriello, A

AU - Charbonnel, B

AU - Hanefeld, M

AU - Lehmann, R

AU - Malecki, MT

AU - Nesto, R

AU - Pirags, V

AU - Scheen, A

AU - Seufert, J

AU - Sjoholm, A

AU - Tsatsoulis, A

AU - DeFronzo, R

PY - 2010/7/1

Y1 - 2010/7/1

N2 - The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.

AB - The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.

KW - Glucose-lowering therapy

KW - Hyperglycaemia

KW - EASD consensus statement

KW - ADA Consensus Statement

KW - Cardiovascular risk

KW - Type 2 diabetes

KW - Algorithm

U2 - 10.1007/s00125-010-1702-3

DO - 10.1007/s00125-010-1702-3

M3 - Article

C2 - 20352408

SN - 1432-0428

VL - 53

SP - 1258

EP - 1269

JO - Diabetologia

JF - Diabetologia

IS - 7

ER -

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this